Sera Prognostics is developing a biomarker test for predicting very preterm birth.
- NeoGenomics Keeps Liquid Biopsy Consolidation Flowing with New M&A
- These Digital Health and Medtech Companies Are Changing the Game in Maternal Health
- ‘Adversity Can Give Us the Hidden Gift of True Purpose’
- A Digitalization Tipping Point for the Medical Manufacturing Supply Chain
- MCIT Ruling Increases Access to Digital Therapeutic Innovation
- Your New Go-To Guide for Medtech Marketing